topotecan
Aliases
Hycamtin(R)
2 clinical trials
1 product
23 abstracts
2 indications
Indication
NeuroblastomaIndication
RetinoblastomaAbstract
A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation.Org: National Cancer Institute-Cancer Therapy Evaluation Program, Cullgen, Inc.,
Abstract
Efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs: A multicentered retrospective study.Org: Department of Orthopaedics, Zhejiang University, Hangzhou, China, Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, China, Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China, Peking University People’s Hospital, Beijing, China,
Abstract
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.Org: Hospital Sant Joan de Deu,
Abstract
Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.Org: Broward Health, Genmab US, Inc.,
Abstract
REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC).Org: Section of Gynecologic Oncology,
Abstract
PP2A activation as a new therapeutic strategy in neuroblastoma: Making sense out of senescence.Org: Atux Iskay LLC,
Abstract
Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer.Org: Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Philadelphia, PA, National Cancer Center Hospital East, Kashiwa, Japan, Shinjuku-Ku, Japan,
Abstract
Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.Org: Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, Yonsei Cancer Center and Severance Hospital, Seoul, South Korea, Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, The Royal Hospital for Women, Sydney, Australia, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA,
Abstract
Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression.Org: Istituto Europeo Oncologia, Community Health Network, Inc, Wielkopolskie Centrum Onkologii, Department of Obstetrics and Gynecology, Faculty of Medicine,
Abstract
N9: Pilot study of novel shortened induction for high-risk neuroblastoma.Org: Memorial Sloan Kettering Cancer Center,
Abstract
IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC).Org: University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Jilin Cancer Hospital, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Hospital Universitario 12 de Octubre,
Abstract
A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).Org: State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China, Shanghai Xianxiang Medical Technology Co., Ltd, Shanghai, China,
Clinical trial
Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2021-10-21
Clinical trial
Protocol for the Study and Treatment of Participants With Intraocular RetinoblastomaStatus: Active (not recruiting), Estimated PCD: 2023-03-17
Abstract
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.Org: University of Milan-Bicocca, University of California Los Angeles Medical Center, European Institute of Oncology IRCCS, University of Chicago, ImmunoGen,
Abstract
Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.Org: Rush University Medical School, FibroFighters Foundation, Nagourney Cancer Institute, FibroFighters.org, Rush University Medical Center,
Abstract
Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling.Org: mProbe Inc., Stanford University School of Medicine,
Abstract
Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer.Org: Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands Cancer Institute, Leiden University Medical Center, Leiden University,
Abstract
Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.Org: PharmaMar, Istituto Oncologico Veneto IOV-IRCCS, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, The Netherlands Cancer Institute, Institutul Oncologic Prof Dr Ion Chiricută and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania,
Abstract
Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.Org: Children’s Hospital of Philadelphia, Abramson Cancer Center, University of Pennsylvania, Children's Hospital Los Angeles Department of Pediatrics, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital,
Abstract
A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).Org: Institut Gustave Roussy, Villejuif, France, Hospital Universitario 12 de Octubre, Madrid, Spain, Spain,
Abstract
Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).Org: Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), The Christie NHS Foundation Trust, Division of Cancer Sciences, Manchester, United Kingdom, Fox Chase Cancer Center, Philadelphia, PA,
Abstract
IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).Org: Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University, Versailles, France, Institut Curie, Saint Cloud, France, Univ Rouen Normandie, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
Cost-effective analysis of rotational intraperitoneal aerosol chemotherapy (RIPAC) in patients with platinum-resistant ovarian cancer.Org: Seoul National University Hospital, Seoul National University College of Medicine,
Abstract
Safety analysis of lurbinectedin versus topotecan in elderly patients.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Fondazione IRCCS - Istituto Nazionale dei Tumori, Fondazione Policlinico Gemelli IRCCS, Hospital Universitario Virgen de la Victoria, Institut Gustave Roussy,